Document Detail


The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
MedLine Citation:
PMID:  17008270     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ovarian hyperstimulation syndrome (OHSS) is a serious and potentially life-threatening complication following ovarian stimulation for in vitro fertilization (IVF). Coasting is the practice whereby the gonadotrophins are withheld and the administration of human chorionic gonadotrophin (hCG) is delayed until serum oestradiol (E2) has decreased to what is considered to be a safe level, to prevent the onset of OHSS. This study aimed to assess the length of coasting on the reproductive outcome in women at risk of developing OHSS. Coasting was undertaken when the serum E2 concentrations were > or = 17000 pmol/L but < 21000 pmol/L. Daily E2 measurements were performed and hCG was administered when hormone levels decreased to < 17000 pmol/L. Eighty-one women who had their stimulation cycles coasted were grouped according to the number of coasting days. Severe OHSS occurred in one case, which represented 1.2% of patients who underwent coasting because of an increased risk of developing the syndrome. No difference was found between cycles coasted for 1 - 3 days and cycles coasted for > or = 4 days in terms of oocyte maturity, fertilization and embryo cleavage rates. Women in whom coasting lasted for > or = 4 days had significantly fewer oocytes retrieved (P < 0.05) and decreased implantation rate (P < 0.05) compared to those coasted for 1 - 3 days. Pregnancy rate/embryo transfer and live birth rate did not differ between groups. In conclusion, coasting appears to decrease the risk of OHSS without compromising the IVF cycle pregnancy outcome. Prolonged coasting is, however, associated with reduced implantation rates, perhaps due to the deleterious effects on the endometrium rather than the oocytes.
Authors:
Luciano G Nardo; Priya Cheema; Tarek A Gelbaya; Greg Horne; Cheryl T Fitzgerald; Elizabeth H E Pease; Daniel R Brison; Brian A Lieberman
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Human fertility (Cambridge, England)     Volume:  9     ISSN:  1464-7273     ISO Abbreviation:  Hum Fertil (Camb)     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-29     Completed Date:  2007-02-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888143     Medline TA:  Hum Fertil (Camb)     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-80     Citation Subset:  IM    
Affiliation:
Department of Reproductive Medicine, Saint Mary's Hospital, Whitworth Park, Manchester, UK. Luciano.Nardo@cmmc.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chorionic Gonadotropin / administration & dosage
Clinical Protocols
Estradiol / blood
Female
Fertilization in Vitro / adverse effects*,  methods*
Gonadotropin-Releasing Hormone / agonists
Humans
Menotropins / administration & dosage
Ovarian Hyperstimulation Syndrome / etiology,  prevention & control*
Pregnancy
Pregnancy Outcome
Retrospective Studies
Risk Factors
Sperm Injections, Intracytoplasmic / adverse effects,  methods
Time Factors
Chemical
Reg. No./Substance:
0/Chorionic Gonadotropin; 33515-09-2/Gonadotropin-Releasing Hormone; 50-28-2/Estradiol; 61489-71-2/Menotropins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molar pregnancy, childhood cancer and genomic imprinting - is there a link?
Next Document:  Implementation of the NICE guideline - recommendations from the British Fertility Society for nation...